product summary
Loading...
company name :
Krishgen Biosystems
product type :
ELISA/assay
product name :
KRIBIOLISA™ Cevostamab ELISA
catalog :
KBI1753
quantity :
1 x 96 wells
price :
1050 USD
product information
Catalog Number :
KBI1753
Product Name :
KRIBIOLISA™ Cevostamab ELISA
Product Type :
ELISA
Size :
1 x 96 wells
List Price (USD) :
1050 USD
Product Description :
ELISA for the detection of Cevostamab in human serum and plasma. Lead time for this kit is 5 weeks. About the kit: - Uses anti-idiotypic monoclonal antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity. - Recovery rates are between 85 - 115% - Validated as per US FDA guidelines for Bioassays - Developed using the innovator drug as calibrator - Shelf life: 1 year.Cevostamab is a bispecific antibody, designed for the treatment of multiple myeloma. It binds to both the CD3 antigen on cytotoxic T lymphocytes (CTLs) and FCRH5 found on FCRH5-expressing tumor cells. This activates and crosslinks CTLs with FCRH5-expressing tumor cells, which results in the CTL-mediated cell death of FCRH5-expressing tumor cells. FCRH5, an immune receptor translocation-associated protein/Fc receptor homolog (IRTA/FCRH) family member and a B-cell lineage marker, is overexpressed on myeloma cells.
SpeciesSummary :
Human
Packaging :
This ELISA kit comes with a pre-coated plate, concentrated or lyophilized standards, wash solution, subtrate, stop solution and all the required diluents. For the exact contents of the kit, please refer to the datasheet / IFU.
Storage :
2-8 Deg C
Calibration Range :
0 ug/ml - 100 ug/ml
Sensitivity :
7.5 ug/ml
Assay Principle :
This ELISA employs the quantitative sandwich enzyme immunoassay technique to detect and capture the target bispecific antibody. One target protein to which the bsAb binds is pre-coated onto microwells. Samples and standards are pipetted into microwells and the target bsAb drug present in the sample are bound by the capture antibody. Then, the second target protein to which the bsAb binds wtih HRP (horseradish peroxidase) conjugation is then pipetted and wells are incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of bsAb drug in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
Biomarker :
Cevostamab
Regulatory Status :
RUO
Shipping :
2-8 degrees C
company information
Krishgen Biosystems
11331 183rd Street, #413
Cerritos, CA 90703
sales_usa@krishgen.com
http://www.krishgen.com
1-888-970-0827
headquarters: USA